Amazon Now Carries RelSup Dietary Supplements
November 18, 2020 10:01 ET | RelSup
PALM BEACH, FL, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Amazon, the largest online retailer, now carries Relsup’s dietary supplements. “The RelSup team is excited that Amazon now offers our flagship...
RelSup - Reliable Supplements That You Can Trust - Now on Sale at VitaBeauti.com
September 03, 2020 15:02 ET | Nutritional Products International
BOCA RATON, FL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- RelSup’s proprietary nutritional supplements for the liver, digestion, metabolic health, and lactose intolerance are now available at...
RelSup - Reliable Supplements That You Can Trust
August 26, 2020 17:41 ET | RelSup
BOCA RATON, FL, Aug. 26, 2020 (GLOBE NEWSWIRE) -- RelSup, a nutraceutical company in Minnesota, announced this week it is introducing four new dietary supplements to support liver function,...
ritter.jpg
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
November 13, 2019 19:35 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
ritter.jpg
Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance
September 12, 2019 16:15 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
ritter.jpg
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 11, 2019 17:28 ET | Ritter Pharmaceuticals, Inc.
Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...
ritter.jpg
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
July 02, 2019 09:00 ET | Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
ritter.jpg
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
May 07, 2019 09:15 ET | Ritter Pharmaceuticals, Inc.
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
ritter.jpg
Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
November 06, 2018 07:00 ET | Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial  for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
ritter.jpg
Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting
October 09, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...